Takeda Pharmaceutical Company Limited
ORZEYFUL (generic name: obeporepton) FDA approval in the United States News Release
With the FDA approval of ORZEYFUL (obeporepton), it is approved as the first orexin receptor agonist for NT1 treatment. After DEA classification review is completed, it will be launched in the U.S. market via specialty pharmacies. Impact on full-year consolidated results for FY2027 is not currently expected to be significant.
Key Figures
- Approval date: 2026-08-05 (FDA approval mentioned)
- DEA classification decision: expected within 90 days
- Future launch: planned via specialty pharmacies
AI要約
Overview of the News
Takeda Pharmaceutical announced that it has obtained FDA approval for ORZEYFUL (obeporepton). For NT1, this drug demonstrates multiple symptom improvements during daytime and nighttime and is approved as the first orexin receptor agonist. Once the DEA classification review is completed, it will be available in the U.S. market via specialty pharmacies.
Outlook and Impact
DEA classification decision is expected within 90 days after FDA approval, and after approval, treatment options for NT1 patients will expand. This approval is not expected to have a material impact on the full-year consolidated earnings forecast for FY2027. Obeporepton provides a new mechanism of action as an orexin receptor agonist for NT1 treatment.
Takeda Pharmaceutical Company Limited
Company overview · Stock price · Financial data · All IR
